Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2021.03.24

Clean room block

Sai Life Sciences opens new clean room block at its manufacturing campus

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMOs), today announced the opening of a new Clean Room block at its cGMP API & Intermediate Manufacturing campus in Bidar, India.

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences said, “Over the last two years we have been seeing an increase in projects involving commercial products, not just for regulatory starting materials and intermediates, but also final drug substances. This addition of latest generation clean rooms to our facilities expands our capacity while adding versatility to help serve the diverse needs of our customers.”

A notable aspect across all of the company’s infrastructure expansion over the past two years has been to make all new facilities uniformly capable of handling containment down to 1µg/m3. The new 8,500 sq. ft. Clean Room block is the newest addition to this list. Located in the Bidar Manufacturing Campus of the company, it has the following features:

• Four ISO-8 (Class 100,000) Clean Rooms operating at containment level of 1µg/m3 across the operation
• Four parallel crystallizer lines with complete segregation of AHU
• Five versatile dissolution reactors capable of handling various reactions, including if crystallization step is in situ with reaction
• Latest generation Wonderware automation which allows fine ramp control / distillation control to handle critical cooling crystallization and evaporative crystallization
• Versatile sizes of filtration, drying equipment (Filter dryers, Peeler centrifuge, Nauta dryer)
• Various material of construction (SS316, Hastelloy and Glass-lined).
• Separate line for size reduction.
• “Bubble design” with separate gowning / de-gowning areas and airlocks to enable multi-product handling.

Sai Life Sciences began a process of organizational transformation in 2019 reinventing itself as a new generation global CDMO. Through this initiative, named Sai Nxt, the company is investing over US$ 150M (> INR 1000 Cr) to expand and upgrade its R&D and manufacturing facilities, induct top-notch global scientific and leadership talent, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.

Share article

More News

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more

2025.08.13

Peptide Science & Beyond: Masterclass & Fireside Chat with IISc Professor, Dr. Jayanta Chatterjee

Sai Life Sciences recently hosted Dr. Jayanta Chatterjee, Associate Professor at the Indian Institute of Science (IISc), Bangalore, for two enriching sessions at its campus. The first was the Masterclass Lecture Series, where Dr. Chatterjee addressed a group of scientists at Sai Life Sciences on “Our Adventures in the de novo Design of Helical Macrocyclic […]
Read more

2025.08.13

From vendor to vanguard: Reimagining India’s role in global life sciences

In a recent article published in ET Edge titled, ‘From Vendor to Vanguard: Reimagining India’s Role in Global Life Sciences,’ Krishna Kanumuri, MD & CEO, Sai Life Sciences, highlighted India’s rapidly unfolding transformation from a vendor to an innovation leader in the global life sciences ecosystem.You can read the full article here: From vendor to vanguard: […]
Read more

2025.08.08

Sai Life Sciences Limited Reports Revenue growth of 77% YoY

Q1FY26 Revenue at ₹496 Cr; EBITDA at ₹125 Cr; Net Profit at ₹60 Cr. Hyderabad, August 08, 2025: Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, Contract Research, Development and Manufacturing Organization (CRDMO) announced its financial results for the first quarter of Fiscal year 2026. Financial Performance: Particulars (₹ crores) Q1FY26 […]
Read more